Post Spotlights ICER’s Remdesivir Pricing Models

May 24, 2020

The authors of a recent Health Affairs blog post highlight the Institution for Clinical and Economic Review’s (ICER) pricing recommendations for Gilead’s remdesivir.

ICER’s value-based price for the drug raises several questions, the authors, Joshua Cohen, Peter Neumann and Daniel Ollendorf, write, including the exclusion of societal benefits.

“Ignoring remdesivir’s potential non-health benefits also seems a glaring omission, as the United States nears two months of shutdown, a main goal of which has been to ‘flatten the curve’ and hence protect the health care system from becoming overwhelmed,” they write.

To read the full blog post, click here.

Share This Story!